Bio-Path: Jumps on completing safety check of cancer treatment trial

Bio Path Holdings

05/04/2021 13:40

** Biotech firm's shares  BPTH.O  jump 16.5% to $8.33
premarket 
    ** Stock among top pct gainers across U.S. exchanges
    ** Co completes safety run-in of stage 2 of its mid-stage
trial testing treatment, BP1001, for acute myeloid leukemia in
combination with frontline therapies
    ** We are particularly pleased with the clean side effect
profile and lack of toxicity shown in this segment of the study-
co
    ** The mid-stage trial continues with 21 patients currently
enrolled across three cohorts  urn:newsml:reuters.com:*:nGNX4KCs3m
    ** Stock up 51.5% in the last 12 months

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))